Salesforce looks to strengthen its AI platform, a positive note for J&J
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Taking the long view on ibrutinib in CLL
Professor Stephan Stilgenbauer explains how BTK inhibitors remain the gold standard of treatment for the slow-growing haematological malignancy…
Wes Moss’ $1.6 Million Portfolio Rule Quietly Beats Government Pensions for Affluent Retirees
Quick Read If a $50,000 pension is worth $1 million in bond-equivalent wealth, then a $1.6 million portfolio…
An unloved health-care stock gets welcome nod in AI-obsessed market
Health-care stocks aren’t getting much of a look in this AI-driven market. That makes a Wall Street upgrade…
Johnson & Johnson CEO: America’s innovation advantage starts with health
Johnson & Johnson CEO: America’s innovation advantage starts with health | Fortune Joaquin Duato is Chairman and Chief…
The Nationwide Social Security Survey Says Most Americans Are Flying Blind on Benefits, Here’s the Income Strategy That Fills the Gap
Quick Read The Stocks: Johnson & Johnson (JNJ) has extended a 64-year streak of consecutive annual dividend increases…
J&J starts head-to-head PFA trial against Boston Scientific device
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free…
The money to AI stocks is a problem, and how it can be fixed
We do not have enough money coming into this market. The funds flow only to stocks tied to…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…
Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify…
How The Narrative On Johnson & Johnson (JNJ) Is Shifting With New Targets And Litigation Risks
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
ICOTYDE Approval Adds New Growth Angle To Johnson & Johnson Valuation Story
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…